Breaking News

Intas Pharmaceuticals Receives Another Warning Letter from FDA

Cites failure to ensure drug products manufactured at Gujarat, India plant comply with cGMP.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Intas Pharmacuticals has received another warning letter from the U.S. FDA regarding its plant in Gujarat, India. The warning letter posted November 28 names four issues found at the plant following a 12-day site inspection in May 2023. According to the FDA, the company failed to ensure drug products manufactured at the site comply with current Good Manufacturing Practice (cGMP) regulations.   The letter cites manufacturing violations, quality control issues, and compromised data integrity. Th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters